NanoString Eligible to Receive up to
DLBCL is a heterogeneous group of cancers classified together on the
basis of morphology, immunophenotype, genetic alterations and clinical
behavior, and represents the most common form of Non-Hodgkin Lymphoma.
According to the
Under the collaboration agreement with Celgene,
"Biomarker-driven clinical trials are the future of clinical oncology.
Our collaboration with
The upfront payment and a portion of the success-based milestone
payments are intended to cover NanoString's costs for clinical
development of the IVD. Included in such
"We are excited to work with Celgene to help improve the lives of
For more information, please visit www.nanostring.com.
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements
include statements regarding plans for development, regulatory approval
and commercialization of an IVD assay for DLBCL, future payments that
may or may not be received by
News Provided by Acquire Media